The therapeutic efficacy for limb ischemia by transplantation of mobilized peripheral blood cells before and after CD34+ cell depletion.
- Author:
Bin ZHOU
1
;
Shu LI
;
Dong-Sheng GU
;
Kai-Hong WU
;
Peng-Xia LIU
;
Zhong-Chao HAN
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Antigens, CD34; Disease Models, Animal; Hematopoietic Stem Cell Transplantation; Hindlimb; blood supply; Humans; Injections, Intramuscular; Ischemia; metabolism; surgery; Leukocytes, Mononuclear; transplantation; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; metabolism
- From: Chinese Journal of Hematology 2007;28(3):194-198
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the mechanism of the therapeutic efficiency of mobilized peripheral blood mononuclear cells (PBMNCs) with and without CD34+ cell depletion in ischemia nude mice.
METHODSAfter femoral ligation of mice, 1 x 10(6) PBMNCs, CD34+ cell depletion PBMNCs, or PBS were intramuscularly injected into the ischemic limb. Blood perfusion, ischemia damage, and capillary density of the limb were observed. VEGF expression in ischemic limbs was assayed by ELISA and immunohistochemistry.
RESULTSPBMNCs transplant greatly improved the recovery of ischemic limbs. At day 28 after surgery, the blood perfusion rate of ischemic limbs recovered to (96.4 +/- 5.6)% from (20.3 +/- 4.2)% in PBMNCs transplanted group, compared with (71.3 +/- 4.4) % in PBS group (P <0.01). Depletion of CD34+ cells reduced the perfusion ratio to (83.8 +/- 5.2)% (P < 0.05). Capillary density in PBMNCs transplanted group was (521 +/- 47)/mm2, while in CD34+ cell-depleted group [ (396 +/- 21)/mm2] (P < 0.05). PBMNCs were found to incorporate into vascular network. VEGF was greatly up-regulated after transplantation of PBMNCs and was secreted in situ.
CONCLUSIONTransplantation of mobilized PBMNCs augments neovascularization in ischemic limb via supply of stem/progenitor cells and angiogenic factors. Depletion of CD34+ cells impaired therapeutic efficacy for limb ischemia.
